Apogee Therapeutics (APGE) Earnings Date & Reports
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications... Show more
APGE is expected to report earnings to fall 33.96% to -69 cents per share on August 17
Apogee Therapeutics (APGE) Q4 2025 Earnings Recap: EPS Beat Fuels Pipeline Optimism
Key Takeaways
- Reported Q4 2025 EPS of -$1.03, beating analyst consensus estimates of -$1.05 by $0.02.
- Full-year 2025 net loss expanded to $255.8 million from $182.1 million in 2024, reflecting increased investments in research and development (R&D).
- Cash, cash equivalents, and marketable securities stood at $902.9 million as of December 31, 2025, up from $731.1 million a year earlier.
- The strong cash position supports operations into the second half of 2028.
- No revenue generated, typical for a clinical-stage biotech focused on immunology therapies.
- Pipeline updates included positive progress on lead candidate zumilokibart for atopic dermatitis (AD), asthma, and eosinophilic esophagitis (EoE).
Earnings Context and Why It Matters
As a clinical-stage biotechnology company developing novel therapies for inflammatory diseases, Apogee Therapeutics' Q4 2025 earnings underscore its transition from early-stage research to advancing multiple clinical programs. Investors closely watch cash burn rates and pipeline milestones amid a competitive immunology landscape dominated by established treatments like DUPIXENT. The wider net loss signals aggressive R&D spending to accelerate trials, while the bolstered balance sheet mitigates dilution risks. With shares trading near 52-week highs post-earnings, this report provides critical insights into execution risks, funding runway, and potential for breakthrough data readouts that could drive significant value inflection points.
Apogee Therapeutics reported no collaboration or product revenue in Q4 2025, aligning with its pre-commercial status. For the full year, total operating expenses rose 32% to $285.6 million, driven by R&D expenses of $214.7 million (up 28% year-over-year) and general and administrative (G&A) expenses of $70.9 million (up 45%). This resulted in a full-year net loss of $255.8 million, or approximately -$4.22 per share, compared to $182.1 million in 2024.
Q4 EPS came in at -$1.03, exceeding consensus expectations and demonstrating controlled spending relative to forecasts. The company's cash position ended the year at $902.9 million, bolstered by prior capital raises, providing substantial flexibility for ongoing and planned trials. No formal guidance was issued, but management reaffirmed commitment to key milestones.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions in dynamic markets like biotech.
Market Reaction and Investor Sentiment
Following the March 2, 2026 release, Apogee Therapeutics shares experienced a muted pre-market reaction but closed modestly higher, reflecting balanced views on the EPS beat and wider losses. Investor sentiment remains positive, supported by the extended cash runway and pipeline catalysts. Analysts maintain "Strong Buy" ratings with price targets averaging around $117, citing clinical progress as a key driver amid biotech sector volatility.
Forward Outlook and Key Factors to Monitor
Apogee's $902.9 million cash pile funds operations into the second half of 2028, reducing near-term financing pressures but warranting vigilance on quarterly burn rates, which averaged over $60 million in late 2025.
Pipeline execution tops the watchlist, with APEX Phase 2 Part A 52-week data for zumilokibart in AD already released post-earnings and Part B 16-week results due in Q2 2026. Phase 3 initiation in AD is slated for H2 2026, alongside interim data from asthma, EoE, and head-to-head combo trials (APG279 vs. DUPIXENT). Success here could validate quarterly dosing advantages over competitors.
Broader factors include regulatory feedback, enrollment timelines, and competitive dynamics in immunology. Investors should track 10-Q filings for Q1 2026 burn and any partnership announcements, as these will shape trajectory toward potential 2029 commercialization.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
Industry Biotechnology